BDRX
Biodexa Pharmaceuticals Plc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (gnps) with a core focus on therapeutics for diabetes and cancer. midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. in 2012, midatech established midasol therapeutics lp, a strategic joint venture with monosol rx llc to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. midasol’s lead product, midaform™ insulin pharmfilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter phase ii clinical studies in 2014. these technologies are also being evaluated in the diabetes area by a major us pharmaceutical company. midatech’s unique gnp technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. multiple drug molecules can b
Market Cap: 305 Thousand
Primary Exchange: NASDAQ
Website: http://www.midatechpharma.com/
Shares Outstanding: 237 Thousand
Float: 0
Dividend: 0.0 (0.0%)
Beta: 2.0646809417657503
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 150 trading days
From: 2023-08-31 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|